Friday , December 13 2019
Home / BUSINESS / EQUITIES / Lupin gains on launching generic KCI for Oral Solution
Lupin gains on launching generic KCI for Oral Solution

Lupin gains on launching generic KCI for Oral Solution

Lupin is currently trading at Rs. 748.00, up by 1.70 points or 0.23% from its previous closing of Rs. 746.30 on the BSE.

The scrip opened at Rs. 747.00 and has touched a high and low of Rs. 754.35 and Rs. 740.70 respectively. So far 24772 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 905.90 on 04-Dec-2018 and a 52 week low of Rs. 646.20 on 07-Oct-2019.

Last one week high and low of the scrip stood at Rs. 759.35 and Rs. 721.10 respectively. The current market cap of the company is Rs. 33785.33 crore.

The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.

Lupin has launched Potassium Chloride (KCI) for Oral Solution USP, 20 mEq, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

The company’s Potassium Chloride for Oral Solution USP, 20 mEq, is the generic equivalent of Pharma Research Software Solution, LLC’s Potassium Chloride for Oral Solution USP, 20 mEq, and is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.

Potassium Chloride for Oral Solution USP, 20 mEq, had an annual sales of approximately $90 million in the U.S. (IQVIA MAT September 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.